COMPARISON OF A NOVEL BIODEGRADABLE STENT MAGMARIS WITH DRUG ELUTING RESOLUTE ONYX STENT: SAFETY AND 12 MONTH OUTCOMES

2023

Закрытый доступ Метаданные (CSL-JSON)
DOI 10.53511/pharmkaz.2023.99.27.004
Достоверность данных 70 средняя
Как считается эта оценка

Складывается из проверяемых признаков самой записи: есть ли у статьи DOI, сколько независимых источников подтвердили её данные, заполнены ли обязательные поля и насколько свежо последнее подтверждение. Снижают оценку расхождения между источниками и отсутствие идентификатора. Значение от 80 означает, что запись опубликована без дополнительной проверки; от 60 до 79 — что она опубликована с пониженной достоверностью и ручная проверка желательна. Запись, выверенную редактором вручную, пересчёт не опускает ниже 90. Это оценка наших данных о статье, а не оценка самой статьи.

Аннотация

stent implantation is effective method of overcome critical vessel narrowing and restore normal flowing of blood in affected ones in patients with сoronary artery disease. Using biodegradable stent platform was the next step of treatment evolution and innovative idea for reducing complication. Purpose of the study: : to determine and compare the efficacy, safety and outcomes of implantation of a biodegradable Magmaris and drug eluting Resolute Onyx stent in patients with сoronary artery disease in 12-month follow-up. Material and methods: The single-center prospective study included 50 patients with coronary heart disease who underwent stent implantation (Magmaris, main group – 25 patient, Resolute Onyx, control group - 25 patient). Inclusion criteria: verified coronary artery lesion by angiographic method, signed voluntary informed consent of the patient to participate in the study. The exclusion criteria: the presence of chronic occlusion of the coronary vessel, calcification, acute myocardial infarction, restenosis of a previously implanted stent. Results: after stent implantation there were statistically approved positive dynamic both in severity of angina pectoris signs and in severity of heart failure (p=0.002 and p=0.012 respectively). Evidence of the first endpoints was only in Resolute Onyx group where in 1 case occurred stroke after 12 month of implantation (n=1, p=0.625). Death and myocardial infarction were not recorded. Two patient developed restenosis (8%) after stenting in main group (p=0.422), thrombosis was documented in both groups: one case after Magmaris and two cases after Resolute Onyx implantations (p=0.512). Conclusion: using of biodegradable Magmaris and drug eluting Resolute Onyx stents demonstrated good clinical effects and comparable efficacy and safety in patients with сoronary artery disease in 12-month follow-up.